Modern treatment of acute cystitis in patients with diabetes mellitus

Objective. To study the efficacy and tolerability of Urinalgin F in the treatment of acute cystitis in women with diabetes, as well as to evaluate the effect and tolerability of the dietary supplement Urinal Active in maintaining the function of the urinary system.

Material and methods. A scientific work was conducted at three clinics in the Perm Krai on the use of Urinalgin F in combination with the antibiotic cefixime for the treatment of acute cystitis in 74 women aged 18 to 89 years with diabetes. The ACSS International Cystitis Scale, a visual analog scale (VAS) for pain, and laboratory and bacteriological tests were used. The main group consisted of 37 women who orally received Urinalgin F at a dose of 200 mg 3 times a day for 2 days and cefixime at 400 mg once a day for 7 days. The comparison group consisted of 37 women who orally received cefixime at the same dose for 7 days and drotaverine hydrochloride at 80 mg 3 times a day for 2 days. To further support normal urinary function, Urinal Active was administered to 37 women in the main group in monthly courses of 14 days for 6 months. The second group received no additional supplements.

Results. In the main group, a pronounced analgesic and antidysuric effect of the drug Urinalgin F was established, confirmed by the analysis of the ACSS and VAS scales. The clinical efficacy (recovery) of combination therapy with Urinalgin F and cefixime was 94.6%, bacteriological efficacy was 91.4%, and the period of temporary disability was reduced by 30.8%. In the comparison group, clinical (89.2%) and bacteriological (84.9%) efficacy were significantly lower. Urinalgin F had one (2.7%) side effect of nausea. During a follow-up examination after 6 months, it was found that Urinal Active contributed to a significant improvement in bladder health: 94.6% of those examined had a normal urine test, and 97.3% had no bacteriuria. Compared with the control group, which did not use additional means, in the group using the Urinal Active complex, the number of patients with bacteriuria decreased by 8 times, and the number of relapses of acute cystitis decreased by 9 times (2.7% versus 24.3%). The overall treatment duration was reduced by 59.1%. A favorable tolerability profile of the Urinal Active complex was noted (no adverse events were reported).

Conclusion. Combination therapy of acute cystitis in women suffering from diabetes mellitus with the selective uroanalgesic drug Urinalgin F and the antibiotic cefixime has high clinical and bacteriological efficacy. Urinalgin F is well tolerated by patients with diabetes, significantly eliminates pain and dysuric symptoms of cystitis, and helps to reduce the duration of treatment. Compared with the control group, which did not use additional means, in the group using the Urinal Active complex, normalization of the urinary system condition can be observed, an 8-fold decrease in the number of women with bacteriuria, and a 9-fold decrease in the number of cystitis relapses.